<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Okamoto LE</submitter><funding>NCATS NIH HHS</funding><funding>NHLBI NIH HHS</funding><pagination>489-497</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11839338</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>82(3)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The cholinesterase inhibitor pyridostigmine is used to treat orthostatic hypotension by facilitating cholinergic neurotransmission in autonomic ganglia, thereby harnessing residual sympathetic tone to increase blood pressure (BP) preferentially in the upright posture. We hypothesized that less severe autonomic impairment was associated with greater pressor responses to pyridostigmine.&lt;h4>Methods&lt;/h4>To identify predictors of pressor response, linear regression analyses between the effect of pyridostigmine on upright BP and markers of autonomic impairment were retrospectively conducted on 38 patients who had a medication trial with pyridostigmine (60 mg single dose).&lt;h4>Results&lt;/h4>Pyridostigmine increased upright BP by 4±2/3±2 mm Hg but with a wide range of responses (-2</pubmed_abstract><journal>Hypertension (Dallas, Tex. : 1979)</journal><pubmed_title>Clinical Correlates of Efficacy of Pyridostigmine in the Treatment of Orthostatic Hypotension.</pubmed_title><pmcid>PMC11839338</pmcid><funding_grant_id>UL1 TR002243</funding_grant_id><funding_grant_id>R01 HL161095</funding_grant_id><funding_grant_id>R01 HL144568</funding_grant_id><funding_grant_id>R01 HL122847</funding_grant_id><funding_grant_id>R01 HL149386</funding_grant_id><funding_grant_id>R01 HL142583</funding_grant_id><funding_grant_id>R01 HL170140</funding_grant_id><pubmed_authors>Black BK</pubmed_authors><pubmed_authors>Muldowney JA</pubmed_authors><pubmed_authors>Walsh E</pubmed_authors><pubmed_authors>Tarpara K</pubmed_authors><pubmed_authors>Diedrich A</pubmed_authors><pubmed_authors>Peltier A</pubmed_authors><pubmed_authors>Okamoto LE</pubmed_authors><pubmed_authors>Gamboa A</pubmed_authors><pubmed_authors>Habermann R</pubmed_authors><pubmed_authors>Paranjape SY</pubmed_authors><pubmed_authors>Shibao CA</pubmed_authors><pubmed_authors>Biaggioni I</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical Correlates of Efficacy of Pyridostigmine in the Treatment of Orthostatic Hypotension.</name><description>&lt;h4>Background&lt;/h4>The cholinesterase inhibitor pyridostigmine is used to treat orthostatic hypotension by facilitating cholinergic neurotransmission in autonomic ganglia, thereby harnessing residual sympathetic tone to increase blood pressure (BP) preferentially in the upright posture. We hypothesized that less severe autonomic impairment was associated with greater pressor responses to pyridostigmine.&lt;h4>Methods&lt;/h4>To identify predictors of pressor response, linear regression analyses between the effect of pyridostigmine on upright BP and markers of autonomic impairment were retrospectively conducted on 38 patients who had a medication trial with pyridostigmine (60 mg single dose).&lt;h4>Results&lt;/h4>Pyridostigmine increased upright BP by 4±2/3±2 mm Hg but with a wide range of responses (-2</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2026-07-16T23:26:40.201Z</modification><creation>2026-07-12T03:11:32.045Z</creation></dates><accession>S-EPMC11839338</accession><cross_references><pubmed>39727053</pubmed><doi>10.1161/hypertensionaha.124.24050</doi><doi>10.1161/HYPERTENSIONAHA.124.24050</doi></cross_references></HashMap>